Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 2Multiple Endocrine Neoplasia Type 1 2Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Thymus Neoplasms 1Pituitary Neoplasms 1Pheochromocytoma 1Parathyroid Diseases 1Paraganglioma 1Pancreatic Neoplasms 1Obesity 1Midgut Neuroendocrine Tumors 1High Grade Neuroendocrine Neoplasms 1Brain Neoplasms 1Atherosclerosis 1Adrenocortical Carcinoma 1

Interventions

pasireotide 7Cabergoline 7Surgical Procedures, Operative 4Temozolomide 3Propofol 3Hydrocortisone 3Dexmedetomidine 3lanreotide 2Sevoflurane 2Saline Solution 2Rosiglitazone 2Radiotherapy 2Radiosurgery 2Proton Therapy 2Octreotide 2Human Growth Hormone 2Dexamethasone 2Desflurane 2Aminolevulinic Acid 2pegvisomant 1parecoxib 1lutetium Lu 177 dotatate 1loxoprofen 1farletuzumab 1entinostat 1corticorelin ovine 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Visual Field Tests 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pituitary Neoplasms × Blood Specimen Collection × Endocrine × Clear all
NCT03465618 2026-05-01

A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
17 enrolled
CNSEndocrine

Brain Neoplasms, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡